Human Epididymis Protein 4 in Endometrial Carcinoma
Maneno muhimu
Kikemikali
Maelezo
Human epididymis protein 4, a putative protease inhibition containing two Whey Acid Protein domains, is significantly increased in the endometrioid subtype of endometrial carcinoma.
Tissue microarray and polymerase chain reaction studies confirmed a high level of human epididymis 4 expression in both endometrioid and serous types of endometrial carcinoma , these results are consistent with those from other laboratories showing increased human epididymis protein 4 messenger ribonucleic acid and protein expression in endometrial cancer tissues.
Subsequent investigation demonstrated that human epididymis protein 4 are detectable in various normal tissues with varying expression levels, yet their levels are significantly increased in endometrial carcinoma compared to normal endometrium.
Human epididymis protein 4 ( HE4) is a member of the whey-acidic protein family and it is . Human epididymis protein 4 was first isolated from the human epididymis .
This protein is also known as epididymal secretory protein E4, major epididymis specific protein E4 and putative protease inhibitor WAP5. WFDC-2 gene product was originally thought to be a protein specifically expressed in the epididymis and was dubbed as a tissue marker for the same.
Angioli etal 2013, found HE4 cutoff of 70pmol/l yields the best sensitivity and specificity for detecting endometrial cancer (59.4%) sensitivity and 100% specificity) with a positive predictive value 100% and negative predictive value equal to 71.52% for the 70 pmol/l cutoff, also found that HE4 marker was never increased in patients with benign diseases Kalogera etal 2012 found that HE4 is elevated in high proportion of endometrial cancer patients and it is correlated with myometrial invasion (> 50% P< 0.00) also found that lymph node, statue correlates with the HE4 values there is a statistical significant difference comparing stage I versus stage III (P < 0.0010).
These findings suggest that HE4 could be useful as a preoperative indicator to identify patients suitable for pelvic and para aortic lymphadenectomy.
Tarehe
| Imethibitishwa Mwisho: | 07/31/2018 |
| Iliyowasilishwa Kwanza: | 02/28/2018 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 03/05/2018 |
| Iliyotumwa Kwanza: | 03/06/2018 |
| Sasisho la Mwisho Liliwasilishwa: | 08/12/2018 |
| Sasisho la Mwisho Lilichapishwa: | 08/13/2018 |
| Tarehe halisi ya kuanza kwa masomo: | 11/30/2017 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 05/31/2018 |
| Tarehe ya Kukamilisha Utafiti: | 07/29/2018 |
Hali au ugonjwa
Uingiliaji / matibabu
Diagnostic Test: Human epididymis protein 4
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| endometrial carcinoma( cases) 42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4 | |
| benign diseases(control) 42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4 |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 45 Years Kwa 45 Years |
| Jinsia Inastahiki Kujifunza | Female |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Age (45 - 70 yr old). Exclusion Criteria: 1. Age more than 70 yr and less than 40 yr. 2. Abnormal cardiac hematological renal hepatic functions. 3. Breast cancer or other malignancies. 4. Concomitant benign and for malignant adnexal pathologies. 5. Hormonal medication. 6. Patient taking or having chemo-radiotherapy. 7. Patients unfit for surgical intervention. 8. Smoker. |
Matokeo
Hatua za Matokeo ya Msingi
1. Relation between preoperative level of human epididymis protein 4 and surgicopathological staging of endometrial carcinoma [one week]
